August 7, 2017 — Profound Medical Corp. recently announced that all closing conditions have been satisfied and it has completed the acquisition of Philips’ Sonalleve magnetic resonance-high-intensity focused ultrasound (MR-HIFU) business.
Sonalleve MR-HIFU is a therapeutic platform that combines real-time MR imaging and thermometry with high-intensity focused ultrasound to enable precise and incision-free ablation of diseased tissue.
Philips will continue to distribute Profound’s Tulsa-Pro system, which is designed specifically for ablation of prostate tissue and also uses real-time MR imaging with thermal ultrasound for precise ablation. In addition, Philips and Profound have now expanded this non-exclusive strategic sales relationship to include distribution of Sonalleve MR-HIFU. For a limited time, Philips will also provide other services, including, but not limited to, manufacturing and installation.
With the completion of this acquisition, Profound becomes the only company to provide a therapeutics platform that provides the precision of real-time MR imaging combined with the safety and ablation power of directional (inside-out) and focused (outside-in) ultrasound technology for the incision-free ablation of diseased tissue, according to the company.
For more information: www.profoundmedical.com
October 19, 2026 
